Wells Fargo Maintains Overweight on Amrize, Lowers Price Target to $65

Benzinga Newsdesk www.benzinga.com Negative 85.5%

Neg 85.5% Neu 0% Pos 0%

Wells Fargo analyst Timna Tanners maintains Amrize (NYSE:AMRZ) with a Overweight and lowers the price target from $66 to $65.